Pharmacogenomic Information on Hydralazine

Pharmacogenomic Information

 DrugTherapeutic Area*BiomarkerReferenced
Labeling Sections
HydralazineCardiologyNAT1-2NAT1-2 slow acetylatorsClinical Pharmacology


* Therapeutic areas do not necessarily reflect the CDER review division.
† Standard nomenclature is used for genes as per the Human Genome Organization symbol, cytogenetic abnormalities as per the International System for Human Cytogenetic Nomenclature, or other conventions.
‡ Common terminology listed based on available data with labeling language in parentheses.


back to Table of Pharmacogenomic Biomarkers in Drug Labeling

Page Last Updated: 08/15/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English